1.34 USD
+0.06
4.69%
Updated Aug 26, 3:34 PM EDT
1 day
4.69%
5 days
11.67%
1 month
-1.47%
3 months
6.35%
6 months
-18.29%
Year to date
-14.65%
1 year
-43.70%
5 years
-79.03%
10 years
-71.91%
 

About: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Employees: 281

0
Funds holding %
of 7,433 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

532% more call options, than puts

Call options by funds: $278K | Put options by funds: $44K

6% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 51

2% less capital invested

Capital invested by funds: $209M [Q1] → $206M (-$3.46M) [Q2]

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

2% less funds holding

Funds holding: 155 [Q1] → 152 (-3) [Q2]

4.6% less ownership

Funds ownership: 80.9% [Q1] → 76.3% (-4.6%) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for CERS.

Financial journalist opinion

Based on 4 articles about CERS published over the past 30 days

Neutral
Business Wire
1 day ago
The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transf.
The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions
Neutral
Business Wire
5 days ago
Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 A.M. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of the company's website at ir.cerus.com/events-and-presentations/events-and-webcasts/. A replay will be available for 30 days after the event. ABOUT CERUS Cerus C.
Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025
Neutral
Seeking Alpha
2 weeks ago
Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Kevin D. Green - VP of Finance & CFO Vivek K.
Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript
Neutral
Business Wire
2 weeks ago
Cerus Corporation Announces Second Quarter 2025 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. “With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next generati.
Cerus Corporation Announces Second Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.
Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025
Neutral
Business Wire
1 month ago
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it has been awarded an additional $7.2 million contract amendment by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of lyophilized Pathogen Reduced, Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, and, as lyophilized, LyoIFC) to treat bleeding due to trauma. This additional award is additive t.
Cerus Corporation Announces Additional Department of Defense Award to Advance Care for Major Hemorrhage in Traumatic Injury
Neutral
Business Wire
1 month ago
Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory review for INTERCEPT RBC is advancing ahead of plan and that TÜV-SÜD, our Notified Body, has completed their review of the clinical module and transferred information to the State Institute for Drug Control (SÚKL) in the Czech Republic, for consultation. Reaching this meaningful milestone enables SÚKL.
Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update
Neutral
Business Wire
2 months ago
Cerus Corporation Celebrates World Blood Donor Day 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, “Give blood, give hope: together we save lives” is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and exp.
Cerus Corporation Celebrates World Blood Donor Day 2025
Neutral
Business Wire
2 months ago
Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relati.
Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Neutral
Business Wire
2 months ago
Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. “The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells,” s.
Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan
Charts implemented using Lightweight Charts™